Zacks: Brokerages Anticipate Crispr Theraptc (CRSP) Will Announce Earnings of -$0.60 Per Share
Brokerages expect Crispr Theraptc (NASDAQ:CRSP) to post ($0.60) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Crispr Theraptc’s earnings, with the lowest EPS estimate coming in at ($0.68) and the highest estimate coming in at ($0.51). Crispr Theraptc posted earnings per share of ($2.77) during the same quarter last year, which would indicate a positive year-over-year growth rate of 78.3%. The business is expected to issue its next quarterly earnings results on Tuesday, November 28th.
According to Zacks, analysts expect that Crispr Theraptc will report full year earnings of ($2.46) per share for the current financial year, with EPS estimates ranging from ($2.49) to ($2.43). For the next fiscal year, analysts expect that the business will post earnings of ($3.03) per share, with EPS estimates ranging from ($3.09) to ($2.96). Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow Crispr Theraptc.
Crispr Theraptc (NASDAQ:CRSP) last posted its earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.06. The company had revenue of $3.60 million for the quarter, compared to analyst estimates of $3.29 million. Crispr Theraptc had a negative return on equity of 47.46% and a negative net margin of 406.61%. The business’s revenue for the quarter was up 350.0% compared to the same quarter last year.
CRSP has been the topic of several research analyst reports. Cann initiated coverage on Crispr Theraptc in a research report on Monday, July 17th. They set a “market perform” rating on the stock. Barclays PLC reiterated a “buy” rating and set a $29.00 price target on shares of Crispr Theraptc in a research report on Friday, September 8th. SunTrust Banks, Inc. initiated coverage on Crispr Theraptc in a research report on Thursday, July 13th. They set a “hold” rating and a $16.00 price target on the stock. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a research report on Tuesday, July 18th. Finally, Chardan Capital reiterated a “buy” rating on shares of Crispr Theraptc in a research report on Monday, August 14th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $23.08.
In related news, Director Kurt Von Emster sold 50,477 shares of Crispr Theraptc stock in a transaction on Friday, August 4th. The stock was sold at an average price of $17.81, for a total value of $898,995.37. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Tyler Dylan-Hyde sold 15,000 shares of Crispr Theraptc stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $18.57, for a total value of $278,550.00. Following the completion of the transaction, the insider now owns 167,727 shares in the company, valued at $3,114,690.39. The disclosure for this sale can be found here. Insiders sold a total of 444,010 shares of company stock worth $8,617,089 over the last 90 days. Insiders own 39.98% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Credit Suisse AG acquired a new stake in shares of Crispr Theraptc in the first quarter worth $1,742,000. Hershey Trust Co. acquired a new stake in shares of Crispr Theraptc in the third quarter worth $768,000. Vanguard Group Inc. acquired a new stake in shares of Crispr Theraptc in the second quarter worth $273,000. Moloney Securities Asset Management LLC acquired a new stake in shares of Crispr Theraptc in the third quarter worth $235,000. Finally, ARK Investment Management LLC acquired a new stake in shares of Crispr Theraptc in the second quarter worth $206,000. Institutional investors and hedge funds own 25.50% of the company’s stock.
About Crispr Theraptc
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with Analyst Ratings Network's FREE daily email newsletter.